Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis
Open Access
- 1 August 2020
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 50 (8), 1209-1219
- https://doi.org/10.1002/eji.201948502
Abstract
Ankylosing spondylitis (AS) is associated with autoantibody production to class II MHC-associated invariant chain peptide, CD74/CLIP. In this study, we considered that anti-CD74/CLIP autoantibodies present in sera from AS might recognize CD74 degradation products that accumulate upon deficiency of the enzyme signal peptide peptidase-like 2A (SPPL2a). We analyzed monocytes from healthy controls (n = 42), psoriatic arthritis (n = 25), rheumatoid arthritis (n = 16), and AS patients (n = 15) for SPPL2a enzyme activity and complemented the experiments using SPPL2a-sufficient and -deficient THP-1 cells. We found defects in SPPL2a function and CD74 processing in a subset of AS patients, which culminated in CD74 and HLA class II display at the cell surface. These findings were verified in SPPL2a-deficient THP-1 cells, which showed expedited expression of MHC class II, total CD74 and CD74 N-terminal degradation products at the plasma membrane upon receipt of an inflammatory trigger. Furthermore, we observed that IgG anti-CD74/CLIP autoantibodies recognize CD74 N-terminal degradation products that accumulate upon SPPL2a defect. In conclusion, reduced activity of SPPL2a protease in monocytes from AS predisposes to endosomal accumulation of CD74 and CD74 N-terminal fragments, which, upon IFN-gamma-exposure, is deposited at the plasma membrane and can be recognized by anti-CD74/CLIP autoantibodies.This publication has 33 references indexed in Scilit:
- Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibilityNature Genetics, 2011
- Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk lociNature Genetics, 2010
- Trafficking of MHC Class II in Dendritic Cells is Dependent on but Not Regulated by Degradation of Its Associated Invariant ChainTraffic, 2010
- In vivo control of endosomal architecture by class II‐associated invariant chain and cathepsin SEuropean Journal of Immunology, 2005
- Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic ProteaseScience, 2002
- Plasma Membrane Repair Is Mediated by Ca2+-Regulated Exocytosis of LysosomesCell, 2001
- Release of Signal Peptide Fragments into the Cytosol Requires Cleavage in the Transmembrane Region by a Protease Activity That Is Specifically Blocked by a Novel Cysteine Protease InhibitorPublished by Elsevier BV ,2000
- Essential Role for Cathepsin S in MHC Class II–Associated Invariant Chain Processing and Peptide LoadingImmunity, 1996
- Vinyl Sulfones as Mechanism-Based Cysteine Protease InhibitorsJournal of Medicinal Chemistry, 1995
- Gamma‐interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophagesFEBS Letters, 1995